BioMarin Secures 20% Royalties on Ascendis’s Yuviwel Sales in Global…

Event summary

BioMarin and Ascendis Pharma A/S settled global patent disputes, with Ascendis agreeing to pay BioMarin 20% royalties on Yuviwel sales in the U.S. and 18% in the EU, Brazil, and South Korea until May 2030.
The settlement resolves all pending litigation, including a Section 337 investigation before the U.S. ITC and cases in Brazil, Denmark, Germany, South Korea, and the Northern District of California.
BioMarin will license its CNP technology patents to Ascendis for Yuviwel, covering current and potential indications, including achondroplasia and hypochondroplasia.
The agreement is retroactive to Yuviwel’s first commercial sale, ensuring BioMarin receives royalties on past and future sales.

The big picture

This settlement underscores BioMarin’s ability to monetize its CNP technology patents, reinforcing its leadership in rare disease therapeutics. The deal highlights the strategic importance of intellectual property in the biotech sector, where patent disputes can significantly impact market access and revenue streams. The agreement also ensures continued access to treatments for children with achondroplasia, a key consideration in the rare disease space.

What we're watching

Royalty Revenue Impact: How the 20% U.S. and 18% international royalty rates will contribute to BioMarin’s financial performance, particularly given the retroactive payments.
Market Competition: Whether this settlement strengthens BioMarin’s position in the rare disease therapeutics market, particularly against Ascendis’s Yuviwel.
Innovation Pipeline: The pace at which BioMarin can advance its next-generation medicines for genetic conditions, leveraging the financial influx from the settlement.